Two 59%+ winners, four above 25% in Aug – How this AI model keeps picking winners
Stephen Furlong, Executive Vice President, CFO, and Treasurer of Neuronetics , Inc. (NASDAQ:STIM), recently executed a sale of the company's common stock. On February 12, Furlong sold 10,845 shares at a weighted average price of $3.83 per share, totaling approximately $41,536. Following this transaction, Furlong's direct holdings in the company amount to 471,727 shares. The transaction occurred amid strong momentum for the $244 million market cap company, which has seen its stock surge 27% in the past week alone.
The sale was a non-discretionary transaction designed to cover tax withholding obligations related to the vesting of a restricted stock unit award. The shares were sold at prices ranging from $3.74 to $3.96 per share. According to InvestingPro analysis, the stock appears overvalued at current levels, with significant price volatility. Investors seeking deeper insights can access comprehensive financial health metrics and 12 additional ProTips through InvestingPro's detailed research reports, available for over 1,400 US stocks.
In other recent news, Neuronetics, a global leader in neuroscience, has announced an underwritten public offering of its common stock, with Canaccord Genuity LLC serving as the sole bookrunner. The offering includes a 30-day option for the underwriter to purchase up to an additional 15% of the shares sold. The completion of this offering depends on market and other conditions, and the final terms are yet to be confirmed.
Simultaneously, Neuronetics has reported its preliminary unaudited revenue for the fourth quarter and the full year of 2024, and provided financial guidance for 2025. The company announced revenues of $22.1 million for the fourth quarter and $74.5 million for the year ended December 31, 2024. Post-acquisition adjustments following the recent acquisition of Greenbrook TMS reveal a pro forma consolidated revenue of $34.7 million for the fourth quarter and $129.8 million for the full year of 2024.
Looking ahead to fiscal year 2025, Neuronetics expects a revenue range of $145.0 million to $155.0 million, representing a 12% to 19% increase on a pro forma basis. The company also anticipates a gross margin of approximately 55% and operating expenses between $90.0 million and $98.0 million. These are recent developments that investors should be aware of.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.